Insmed reported $596.57M in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
BioMarin Pharmaceutical USD 1.6B 59.17M Sep/2026
Cytokinetics USD 353.42M 171.99M Sep/2026
DBV Technologies USD 58.5M 4.2M Sep/2026
Gilead Sciences USD 12B 982M Sep/2026
Heron Therapeutics USD 89.85M 2.3M Sep/2026
Insmed USD 596.57M 157.83M Sep/2026
Novartis USD 32.52B 1.15B Sep/2026
Regeneron Pharmaceuticals USD 6.2B 671.5M Sep/2026
Sarepta Therapeutics USD 656.35M 153.44M Sep/2026
Ultragenyx Pharmaceutical USD 389M 38M Sep/2026
Vertex Pharmaceuticals USD 5B 1.06B Sep/2026